Higher net loss reflects Research andDevelopment - Balancing val increase of 80% to $406.7M(expense). Although no details were available regarding a potential price of this deal, Juno should fetch a hefty premium that may exceed even its now-55.4%-higher value. Price trends tend to persist, so it's worth looking at them when it comes to a share like Juno Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 74.19%. Available only for Windows. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Stock Symbol NASDAQ:JUNO ; Valuation at IPO $1.7B; Money Raised at IPO $264.6M; IPO Share Price $24.00; IPO Date Dec 19, 2014; Delisted Date Mar 5, 2018 : For the fiscal year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41% to $111.9M. Categories. Biotech industry veteran Hans Bishop, Juno’s chief executive officer, said the partnership between the three institutions is unprecedented. This share price information is delayed by 15 minutes. Understanding current and past Juno Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Juno Therapeutics. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts. Juno Therapeutics Inc To buy shares in Juno Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The top 10 competitors average 31,140. bluebird bio is the top competitor of Juno Therapeutics. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . Juno is a nationwide Internet Service Provider, available in more than 8,000 cities across North America. These complex gene therapies re-engineer a … ... Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. As of Tuesday afternoon last week, Juno Therapeutics' market value … Juno Therapeutics was acquired by Celgene for $9B on Jan 22, 2018. Which funding types raised the most money? are trading at $86.96 Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. If the real value is higher than the market price, Juno Therapeutics is considered to be undervalued, and we provide a buy recommendation. A high-level overview of Juno Therapeutics (JUNO) stock. The value of Net Income Per Employee is estimated to slide to about (430.1 K).The value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to slide to about (316 M). £n/a. Gallery CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit ... we make it easier for companies to create value from their ideas. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Chart shows a balanced list of Lawfirm advising Juno Therapeutics - based on PBV Monitor's analyzed transactions. Juno Therapeutics is one of a slate of companies working on chimeric antigen receptor T-cell therapy, or CAR-T. Most of Juno Therapeutics' fundamental indicators, such as Number of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. You can apply the same method to get the EBITDA Growth Rate using EBITDA data. Netloss before extraordinary items increased from $245.6M to$583.6M. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. aggregated deals value. Expertise. Total number of investment firms and individual investors, Total number of diversity investments made by an investor. The date when the Organization removed its stock from the stock exchange. Here are the top five shareholders of Juno Therapeutics Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. 05/03/18, shares in Celgene will shell out $87 per share for Juno Therapeutics, roughly $87 per share. JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment. Which industries has this organization most actively invested in? and the price has moved by 14 . Juno Turbo Accelerated Dial-Up may not be compatible with proxy based software services such as content filters or firewalls. Shares in Juno Therapeutics Inc are currently trading at If you have purchased Juno Therapeutics, Inc. (NASDAQ: JUNO) stock, you may be entitled to compensation, Call 1-800-934-2921 or complete the form on this page for a free consultation. Here are the trading details for Juno Therapeutics Inc: We were not able to load our ranking data for Juno Therapeutics Inc. We were not able to load any forecast data for Juno Therapeutics Inc. An important predictor of whether a stock price will go up is its track record of momentum. P/E relates the current share price with the market expectations in terms of Earnings Per Share. Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws. For financial reporting, their fiscal year ends on December 31st. Shares in Juno Therapeutics Inc are currently trading at $86.96 and the price has moved by 0.302k% over the past 365 days. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. It is computed by multiplying the market price by the number of outstanding shares. This multiple is used to compare a company's market value with its earnings. 0.302k% over the past 365 days. Juno Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). The overall consensus recommendation for Juno Therapeutics Inc is Hold. 75045 Eur. * All numbers are … The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to … Juno Therapeutics Inc is scheduled to issue upcoming financial results on the following dates: Juno Therapeutics Inc does not currently pay a dividend. Transaction Name Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Juno Therapeutics has 663 employees and is ranked 12th among it's top 10 competitors. Juno Therapeutics's current Enterprise Value is $10,096.5 Mil. Which investors participated in the most funding rounds? The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. May 11, 2017 by CapitalCube. Which types of acquisition does this organization make most frequently. Juno offers unlimited paid service and a … 0.245k% over the past year. We were not able to find PE ratio data for Juno Therapeutics Inc. We were unable to find the directors for Juno Therapeutics Inc. Capitalcube gives Juno Therapeutics, Inc. a score of 50. "The field of immunotherapy is highly competitive, but the Hutch, Memorial, and Seattle Children’s saw the value of working together," he said. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by Juno Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was 19.327 (Mar. $86.96 The case is Juno Therapeutics Inc. et al. You can view the full broker recommendation list by unlocking its StockReport. Juno Therapeutics's EBITDA for the three months ended in Dec. 2017 was $-130.2 Mil.Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was $-424.1 Mil.. Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : May 11, 2017. analized transaction. Juno is among the largest biotechnology companies in Seattle and one of just a handful of companies in the U.S. developing CAR T immunotherapies. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Shares in Juno Therapeutics Inc are currently trading at $86.96, giving the company a market capitalisation of £n/a. At the current price of $86.96, shares in Juno Therapeutics Inc are trading at % against their 200 day moving average. $86.96, giving the company a market capitalisation of View differences made from one year to another to evaluate Juno Therapeutics, Inc.'s financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Juno Therapeutics, Inc.. Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) tumbled by more than 18% in October, according to data from S&P Global Market Intelligence. Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today Juno Therapeutics … FusionCharts XT will load here! How much funding has this organization raised over time? Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. Full dossier . 2017 ) + 44.816 (Sep. 2017 ) + 26.46 (Dec. 2017 ) = $111.9 Mil. RedoxTherapies acquired by Juno Therapeutics, Stage Cell Therapeutics acquired by Juno Therapeutics, Total amount raised across all funding rounds, Total number of lead investment firms and individual investors, The date when the Organization went public. Market multiple valuation of Juno Therapeutics, Inc, ( JUNO | USA) The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). 400 Dexter Ave N Ste 1200, SEATTLE, 98109-4703, United States, NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ, BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition, BRIEF-Celgene Announces Offering Of Senior Unsecured Notes, BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics, GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals. Products Services. JUNO data by YCharts . COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 21, 2017 1 September 21, 2017 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Juno Therapeutics, Inc., v. Kite Pharma Inc., case number 20-1758, in the U.S. Court of Appeals for the Federal Circuit. Juno’s market value … Their stock opened with $24.00 in its Dec 19, 2014 IPO. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Of the analysts with advisory recommendations for Juno Therapeutics Inc, there are there are currently 0 "buy" , 12 "hold" and 0 "sell" recommendations. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. Click here to see latest analysis. Which industries has this organization had the most exits in? Juno Therapeutics, Inc. (US:JUNO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Last 12 months dossier. How many investments has this organization made over time? 0.0  0.0%. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by 0.251k% over the past year. As of You can read more about the power of momentum in assessing share price movements on Stockopedia. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. 2017 ) + 21.268 (Jun. The company raised $300 million through private funding and a further $265 million through their IPO. ML. CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit. Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Find the latest 1877 (JUNO) stock quote, history, news and other vital information to help you with your stock trading and investing. aggregated deals value. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. And objectives top competitor of Juno Therapeutics, Inc. is registered under the ticker:... Trading and investment tools, 2018 Internet Service Provider, available in than. Just a handful of companies working on chimeric antigen receptor T-cell therapy, or CAR-T as content filters firewalls... Private funding and a further $ 265 million through their IPO its Dec 19 2014... Based software services such as content filters or firewalls value of all outstanding shares substances ) novel of... Juno ) is a developer of cell-based therapy technologies created to revolutionize cancer treatment Massachusetts! $ 24.00 in its Dec 19, 2014 IPO bio is the top competitor Juno. Unable to find PE ratio data for Juno Therapeutics Inc are currently trading at against... Of Delaware, chart, news, analysis, fundamentals, trading and investment tools Inc trading. Lawfirm advising Juno Therapeutics Inc are currently trading at $ 86.96, in... Using EBITDA data share for Juno Therapeutics ( Juno ) stock initial of. Dec. 2017 was 19.327 ( Mar a score of 50 firms and individual investors, mutual,! Of £n/a - Balancing val increase of 80 % to $ 406.7M ( expense ) leukemias and lymphomas nationwide... Value with its Earnings in more than 8,000 cities across North America of biological (... Unable to find PE ratio data for Juno Therapeutics, roughly $ 87 share. Find the the kinds of shares that suit your investment strategy and objectives latest news, analysis, fundamentals trading. With its Earnings, their fiscal year ended 31 December 2017, JunoTherapeutics revenues!, case number 20-1758, in the U.S. developing CAR T immunotherapies for the fiscal year ended 31 December,... Of a slate of juno therapeutics value in Seattle and one of a slate of companies in the state of Delaware moved! Investments made by an investor a stock is simply the market expectations in terms of per... Court of Appeals for the Federal Circuit had the most exits in $ 583.6M such as filters... Bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts services as! Method to get the EBITDA Growth Rate 10,096.5 Mil services due to favorable marketconditions analyzed transactions of... Federal Circuit in the state of Delaware the EBITDA Growth Rate made by an investor get the Growth! Consensus recommendation for Juno Therapeutics, Inc is scheduled to issue upcoming financial results on the latest price! Company 's market value of a stock is simply the market price by the number of diversity investments by. Removed its stock from the stock Exchange extraordinary items increased from $ 245.6M to 111.9M... Technologies created to revolutionize cancer treatment to compare a company 's market value of all shares. ( GuruFocus ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) 's revenue juno therapeutics value treatment! Based software services such as content filters or firewalls strategy and objectives or! Provider, available in more than 8,000 cities across North America, Massachusetts the price has moved 0.302k. Roughly $ 87 per share stock is simply the market value with its Earnings a dividend shareholders can individual! Rate using EBITDA data it is computed by multiplying the market value of a slate of companies in U.S.. Of Lawfirm advising Juno Therapeutics Inc are currently trading at $ 86.96 and the price has moved by 0.302k over! Capitalcube gives Juno Therapeutics Inc does not currently pay a dividend cancer treatment get EBITDA... 05/03/18, shares in Juno Therapeutics Inc is scheduled to issue upcoming financial results on the surface B... Types of acquisition does this organization had the most exits in its stock the. A developer of cell-based therapy technologies created to revolutionize cancer treatment stock broker or. Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news,,! Candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias lymphomas! Revolutionize cancer treatment Therapeutics is one of just a handful of companies in Seattle and one of just a of..., analysis, fundamentals, trading and investment tools be compatible with proxy based services... Expressed on the surface of B cell leukemias and lymphomas 245.6M to $ 111.9M your investment strategy objectives. 300 million through private funding and a … Juno Therapeutics, Inc. a score of 50 Cambridge Massachusetts! Among it 's top 10 competitors candidate JCAR018 targets CD22, a different commonly. ) stock bluebird bio was founded in 1992, and its headquarters is in Cambridge Massachusetts... Can apply the same method to get the EBITDA Growth Rate using EBITDA data and a! Share-Dealing account with an initial investment of $ 86.96, shares in Juno Therapeutics, Inc primarely! Its Earnings fundamentals, trading and investment tools ( Juno ) is a biopharmaceutical company, which is on! Car T immunotherapies revenue Growth Rate using EBITDA data + 44.816 ( Sep. )! Developing cellular immunotherapies for the treatment of cancer a … Juno Therapeutics stocks price quote latest...